A sub-analysis of the Odyssey Outcomes study (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab) investigated the efficacy of the PCSK9 inhibitor alirocumab in 18,924 patients, of whom 17,370 had monovascular (coronary) disease, 1405 had a PVD interesting two vascular beds (coronary and peripheral artery or cerebrovascular), and 149 had PVD in all three vascular beds (coronary, peripheral artery, cerebrovascular). Here, PCSK9 is linked to coronary artery disorder.